Future Perspectives on ADCs in Breast Cancer

Author(s):

Panelists discuss how ongoing clinical trials of investigational antibody-drug conjugates (ADCs) are advancing treatment options for breast cancer, particularly in patients with active brain metastases and advanced disease.

EP: 1.Overview of Current ADCs in Breast Cancer

EP: 2.ADCs in Breast Cancer: Mechanism of Action, and Components

EP: 3.Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials

EP: 4.Expert Perspectives on the Management of SG-Related Neutropenia

EP: 5.Navigating SG-related Diarrhea

EP: 6.Expert Insights: SG Adverse Events Management including Alopecia & Nausea

EP: 7.Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies

EP: 8.Clinical Management Considerations: Pneumonitis associated with T-DXd

EP: 9.Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies

EP: 10.Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer

Now Viewing

EP: 11.Future Perspectives on ADCs in Breast Cancer

EP: 12.Expert Insights: Investigational ADCs Safety Profiles

EP: 13.Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs

Video content above is prompted by the following:

Please review some ongoing clinical trials and studies utilizing investigational ADCs in breast cancer that are in progress that may be interesting. (See below for a few suggestions. Please include others if not included.)
1.Bartsch R. et al. Patritumab deruxtecan (HER3-DXd) in Active Brain Mets. TUXEDO-3 Phase II trial. ASCO 2024 Abstract
2.Bardia A et al, Final Results TROPION-Breast01. ESMO 2023 Abstract.